Article successfully added.

CyFlow™ CD8a PE

CyFlow™ CD8a PE
Alternative Name: Leu2, T8
Antibody: Yes
Antigen: CD8a
Application: Flow cytometry
Clonality: monoclonal
Clone: 53-6.7
Emission Maximum: 576 nm
Excitation Maximum: 496 nm, 565 nm
Field of Interest: Immunophenotyping, MHC
Format/Fluorochrome: PE
Isotype: IgG2a
Laser: Blue , Green, Yellow
Regulatory Status: RUO
Source Species: Rat
Target Species: Mouse
Product number: AA286018

For Research Use Only

$255.00 USD*

Price excludes any applicable taxes plus shipping costs

Concentration Unit mg/mL Concentration 0,5 Quantity 0.1 mg Volume 0.2 mL... more
CyFlow™ CD8a PE
Concentration Unitmg/mL
Concentration0,5
Quantity0.1 mg
Volume0.2 mL
ImmunogenMouse spleen cells
Background InformationCD8a (CD8 α) subunit of CD8 T cell coreceptor is expressed in CD8 α/β heterodimers on majority of MHC I-restricted conventional T cells and thymocytes and in CD8 α/α homodimers on subsets of memory T cells, intraepithelial lymphocytes, NK cells, macrophages and dendritic cells. Regulation of CD8 β level on T cell surface seems to be an important mechanism to control their effector function. Assembly of CD8 α/β but not α/α dimers is connected with formation or localization to the lipid rafts. Recruiting triggered TCR complexes to these membrane microdomains as well as affinity of TCR to MHC I is modulated by CD8, thereby affecting the functional diversity of the TCR signaling.
UsageThe reagent is designed for Flow Cytometry analysis. Suggested working usage is 2·µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Ledbetter JA, Herzenberg LA: Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev. 1979; 47:63‑90. < PMID: 398327 > | Ledbetter JA, Rouse RV, Micklem HS, Herzenberg LA: T cell subsets defined by expression of Lyt‑1,2,3 and Thy‑1 antigens: Two‑parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J Exp Med. 1980 Aug 1; 152(2):280‑95. < PMID: 6156984 > | Takahashi K, Nakata M, Tanaka T, Adachi H, Nakauchi H, Yagita H, Okumura K: CD4 and CD8 regulate interleukin 2 responses of T cells. Proc Natl Acad Sci USA. 1992 Jun 15; 89(12):5557‑61. < PMID: 1608966 > | Grabbe S, Varga G, Beissert S, Steinert M, Pendl G, Seeliger S, Bloch W, Peters T, Schwarz T, Sunderkötter C, Scharffetter-Kochanek K: Beta2 integrins are required for skin homing of primed T cells but not for priming naive T cells. J Clin Invest. 2002 Jan; 109(2):183‑92. < PMID: 11805130 > | Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S: Distinct contribution of IL‑6, TNF‑alpha, IL‑1, and IL‑10 to T cell‑mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004 Aug; 114(4):582‑8. < PMID: 15314695 > | Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY: alpha‑Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol. 2005 Sep 1; 175(5):3309‑17. < PMID: 16116223 > | Bouwer HG, Alberti-Segui C, Montfort MJ, Berkowitz ND, Higgins DE: Directed antigen delivery as a vaccine strategy for an intracellular bacterialpathogen. Proc Natl Acad Sci USA. 2006 Mar 28; 103(13):5102‑7. < PMID: 16549792 > | Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M: IL‑2 in vivo activities and antitumor efficacy enhanced by an anti‑IL‑2 mAb. J Immunol. 2006 Jul 1; 177(1):306‑14. < PMID: 16785526 > | Mochimaru H, Usui T, Yaguchi T, Nagahama Y, Hasegawa G, Usui Y, Shimmura S, Tsubota K, Amano S, Kawakami Y, Ishida S: Suppression of alkali burn‑induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2. Invest Ophthalmol Vis Sci. 2008 May; 49(5):2172‑7. < PMID: 18263815 >